Trial Profile
Planned phase II trial of RG 7624 (NI-1401) in patients with autoimmune disorders
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 22 Sep 2014
Price :
$35
*
At a glance
- Drugs Afasevikumab (Primary)
- Indications Autoimmune disorders
- Focus Therapeutic Use
- Sponsors Genentech
- 22 Sep 2014 New trial record
- 05 Aug 2014 This trial is expected to be initiated in early 2015, according to a Novimmune media release.